Let's talk prostate cancer - Digital Atlas
astellas Amgen lets talk
Let's talk prostate cancer - Digital Atlas
astellas lets talk

Let's talk prostate cancer
Digital Atlas
astellas lets talk
HOME ABOUT INCIDENCE MORTALITY SURVIVAL PROSTATE CANCER CARE QoL POLICIES GUIDELINES PATIENT STORIES LTPC CAMPAIGN RESOURCES CONTACT
HOME ABOUT INCIDENCE MORTALITY SURVIVAL PROSTATE CANCER CARE QoL POLICIES GUIDELINES PATIENT STORIES LTPC CAMPAIGN RESOURCES CONTACT PRIVACY NOTICE COOKIES
Page top is here
blank
PROSTATE CANCER CARE

Access to Specialists

Access to specialist care is crucial for ongoing monitoring of prostate cancer disease progression and ensuring that those affected receive access to the right treatment at the right time.

Review by a multidisciplinary and multi-professional team, including a medical oncologist, a cancer nurse and a radiotherapist is vital to ensure that patients receive a tailored care and treatment plan. Unfortunately, there is no comparative data on access to these medical professionals in Europe.

Data on the number of urologists across Europe suggest that there is considerable variation in access to specialist care across Europe with a particularly low number of urologists in Ireland  and the UK. In 2018 there was one urologist per 64,260 inhabitants in the UK2 compared to one per 14,000 in Germany.3
More needs to be done to ensure equal and timely access to specialist prostate cancer care for those affected no matter where in Europe they live. 

Cost of cancer

Prostate cancer patient outcomes are influenced by several factors, including effective access to timely diagnosis, specialist care and the right treatment at the right time.4 An appropriately funded healthcare infrastructure provides the bedrock for the prostate cancer medical workforce to provide holistic care for those affected. Those countries that invest more in cancer care tend to achieve better patient outcomes.5

National governments should ensure the necessary infrastructure is in place so that patients have timely access to high quality multidisciplinary prostate cancer services at every stage of the treatment and care pathway, as promoted in ECCO's Essential Requirements for Quality Cancer Care.6

Cancer medicines spend

The significant variation in cancer medicines spend across Europe7 suggests that not all men across Europe receive optimal treatment. We are calling on policy makers and health system leaders to ensure that those affected by prostate cancer receive the right treatment at the right time, no matter where in Europe they live.

 

1 European Society of Residents in Urology (ESRU). Countries: Ireland. March 2018. Accessible at https://esru.eu/?q=ireland (last accessed March 2022)
2 British Association of Urological Surgeons and The Specialist Advisory Committee in Urology. Workforce Report. 2018. Accessible at https://www.baus.org.uk/_userfiles/pages/files/publications/Workforce_Report_Sep%202018%20ver%201.1.pdf (last accessed March 2022)
3 European Society of Residents in Urology (ESRU). Countries: Germany. March 2018. Accessible at https://esru.eu/?q=germany (last accessed March 2022)
4 Van Poppel, H et al. White paper on Prostate Cancer, Recommendations for the EU Cancer Plan to tackle Prostate Cancer. European Association of Urology. 2020. Accessible at https://uroweb.org/wp-content/uploads/EAU-Prostate-Cancer-Pca-WhitePaper-Recommendation-for-Recommendations-for-the-EU-Cancer-Plan-May-2020.pdf (last accessed March 2022)
5 Hofmarcher, T et al. Comparator Report on Cancer in Europe in 2019. IHE Report 2019:7
6 Banks, I et al. ECCO Essential Requirements for Quality Cancer Care: Primary care. Critical Reviews in Oncology/Haematology. 2019. 142:187-199
7 Hofmarcher, T et al. Comparator Report on Cancer in Europe in 2019. IHE Report 2019:7. Accessible at https://www.efpia.eu/publications/cancer-comparator-report/cancer-types/prostate-cancer/ (last accessed March 2022)

 

ACCESS TO SPECIALISTS
COST OF CANCER
CANCER MEDICINES SPEND

*Different data sources were used for Belgium, Hungary, Italy, Romania and the UK, which may use data from different years. See references below. No data was found for Cyprus, Luxembourg, Malta and Slovakia.

European Society of Residents in Urology (ESRU). Countries. March 2018. Accessible at https://esru.eu/?q=countries (last accessed March 2022)
Federal Public Service of Public Health, Safety of the Food Chain and the Environment. HWF STATAN 2019 (detailed statistics). 2019. Accessible at https://organesdeconcertation.sante.belgique.be/fr/documents/hwf-statan-2019-statistiques-detaillees (last accessed March 2022)
Boszormenyi-Nagy, G. Report on urological inpatient care based on 2018 data. Urologia Hungarica. Accessible at http://urologiahungarica.hu/index.php/2020/05/12/beszamolo-az-urologiai-fekvobeteg-ellatasrol-a-2018-as-adatok-alapjan/ (last accessed March 2022)
I.Stat. Personale sanitario. Accessible at http://dati.istat.it/Index.aspx?DataSetCode=DCIS_PERS_SANIT (last accessed March 2022)
Institutul National De Statistica. Activitatea Unitatilor Sanitare in Anul 2019. 2020. Accessible at https://insse.ro/cms/sites/default/files/field/publicatii/activitatea_unitatilor_sanitare_anul_2019.pdf (last accessed March 2022)
United Nations, Population Division, Department of Economic and Social Affairs. World Population Prospects 2019. Accessible at https://population.un.org/wpp/Download/Files/1_Indicators%20(Standard)/EXCEL_FILES/1_Population/WPP2019_POP_F01_1_TOTAL_POPULATION_BOTH_SEXES.xlsx (last accessed March 2022)
British Association of Urological Surgeons and The Specialist Advisory Committee in Urology. Workforce Report. 2018. Accessible at https://www.baus.org.uk/_userfiles/pages/files/publications/Workforce_Report_Sep%202018%20ver%201.1.pdf (last accessed March 2022)
Hofmarcher, T et al. Comparator Report on Cancer in Europe in 2019. IHE Report 2019:7. Accessible at https://www.efpia.eu/publications/cancer-comparator-report/cancer-types/prostate-cancer/ (last accessed March 2022)
Hofmarcher, T et al. Comparator Report on Cancer in Europe in 2019. IHE Report 2019:7. Accessible at https://www.efpia.eu/publications/cancer-comparator-report/cancer-types/prostate-cancer/ (last accessed March 2022)